BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 34103517)

  • 1. Large variation in anti-SARS-CoV-2 antibody prevalence among essential workers in Geneva, Switzerland.
    Stringhini S; Zaballa ME; Pullen N; de Mestral C; Perez-Saez J; Dumont R; Picazio A; Pennacchio F; Dibner Y; Yerly S; Baysson H; Vuilleumier N; Balavoine JF; Bachmann D; Trono D; Pittet D; Chappuis F; Kherad O; Kaiser L; Azman AS; ; Guessous I
    Nat Commun; 2021 Jun; 12(1):3455. PubMed ID: 34103517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Geneva, Switzerland (SEROCoV-POP): a population-based study.
    Stringhini S; Wisniak A; Piumatti G; Azman AS; Lauer SA; Baysson H; De Ridder D; Petrovic D; Schrempft S; Marcus K; Yerly S; Arm Vernez I; Keiser O; Hurst S; Posfay-Barbe KM; Trono D; Pittet D; Gétaz L; Chappuis F; Eckerle I; Vuilleumier N; Meyer B; Flahault A; Kaiser L; Guessous I
    Lancet; 2020 Aug; 396(10247):313-319. PubMed ID: 32534626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Seroprevalence of SARS-CoV-2 IgG specific antibodies among healthcare workers in the Northern Metropolitan Area of Barcelona, Spain, after the first pandemic wave.
    Barallat J; Fernández-Rivas G; Quirant-Sánchez B; González V; Doladé M; Martinez-Caceres E; Piña M; Matllo J; Estrada O; Blanco I
    PLoS One; 2020; 15(12):e0244348. PubMed ID: 33370363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts.
    Kataria Y; Cole M; Duffy E; de la Cena K; Schechter-Perkins EM; Bouton TC; Werler MM; Pierre C; Ragan EJ; Weber SE; Jacobson KR; Andry C
    Sci Rep; 2021 May; 11(1):9694. PubMed ID: 33958668
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of SARS-CoV-2 antibodies in pediatric healthcare workers.
    Morris CR; Sullivan P; Mantus G; Sanchez T; Zlotorzynska M; Hanberry B; Iyer S; Heilman S; Camacho-Gonzalez A; Figueroa J; Manoranjithan S; Leake D; Mendis R; Cleeton R; Chen C; Krieger R; Bush P; Hughes T; Little WK; Suthar MS; Wrammert J; Vos MB
    Int J Infect Dis; 2021 Apr; 105():474-481. PubMed ID: 33722686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
    Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
    Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Authors' response: Occupation and SARS-CoV-2 infection risk among workers during the first pandemic wave in Germany: potential for bias.
    Reuter M; Rigó M; Formazin M; Liebers F; Latza U; Castell S; Jöckel KH; Greiser KH; Michels KB; Krause G; Albrecht S; Öztürk I; Kuss O; Berger K; Lampl BMJ; Leitzmann M; Zeeb H; Starke KR; Schipf S; Meinke-Franze C; Ahrens W; Seidler A; Klee B; Pischon T; Andreas Deckert AD; Schmidt B; Mikolajczyk R; Karch A; Bohn B; Brenner H; Holleczek B; Dragano N
    Scand J Work Environ Health; 2022 Sep; 48(7):588-590. PubMed ID: 36153787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study.
    Poustchi H; Darvishian M; Mohammadi Z; Shayanrad A; Delavari A; Bahadorimonfared A; Eslami S; Javanmard SH; Shakiba E; Somi MH; Emami A; Saki N; Hormati A; Ansari-Moghaddam A; Saeedi M; Ghasemi-Kebria F; Mohebbi I; Mansour-Ghanaei F; Karami M; Sharifi H; Pourfarzi F; Veisi N; Ghadimi R; Eghtesad S; Niavarani A; Ali Asgari A; Sadeghi A; Sorouri M; Anushiravani A; Amani M; Kaveh S; Feizesani A; Tabarsi P; Keyvani H; Markarian M; Shafighian F; Sima A; Sadjadi A; Radmard AR; Mokdad AH; Sharafkhah M; Malekzadeh R
    Lancet Infect Dis; 2021 Apr; 21(4):473-481. PubMed ID: 33338441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Difference in SARS-CoV-2 Antibody Status Between Patients With Cancer and Health Care Workers During the COVID-19 Pandemic in Japan.
    Yazaki S; Yoshida T; Kojima Y; Yagishita S; Nakahama H; Okinaka K; Matsushita H; Shiotsuka M; Kobayashi O; Iwata S; Narita Y; Ohba A; Takahashi M; Iwasa S; Kobayashi K; Ohe Y; Yoshida T; Hamada A; Doi T; Yamamoto N
    JAMA Oncol; 2021 Aug; 7(8):1141-1148. PubMed ID: 34047762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High SARS-CoV-2 Prevalence among Healthcare Workers in Cochabamba, Bolivia.
    Saba Villarroel PM; Castro Soto MDR; Undurraga V; Sanz H; Jaldín AM; Ninove L; Nurtop E; Pezzi L; Mohamed Ali S; Amroun A; Seston M; de Lamballerie X
    Viruses; 2022 Jan; 14(2):. PubMed ID: 35215826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
    Marklund E; Leach S; Nyström K; Lundgren A; Liljeqvist JÅ; Nilsson S; Yilmaz A; Andersson LM; Bemark M; Gisslén M
    Front Immunol; 2021; 12():750448. PubMed ID: 34795668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Seroprevalence of anti-SARS-CoV-2 IgG antibodies in the staff of a public school system in the midwestern United States.
    Lopez L; Nguyen T; Weber G; Kleimola K; Bereda M; Liu Y; Accorsi EK; Skates SJ; Santa Maria JP; Smith KR; Kalinich M
    PLoS One; 2021; 16(6):e0243676. PubMed ID: 34111144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-occupational and occupational factors associated with specific SARS-CoV-2 antibodies among hospital workers - A multicentre cross-sectional study.
    Kahlert CR; Persi R; Güsewell S; Egger T; Leal-Neto OB; Sumer J; Flury D; Brucher A; Lemmenmeier E; Möller JC; Rieder P; Stocker R; Vuichard-Gysin D; Wiggli B; Albrich WC; Babouee Flury B; Besold U; Fehr J; Kuster SP; McGeer A; Risch L; Schlegel M; Friedl A; Vernazza P; Kohler P
    Clin Microbiol Infect; 2021 Sep; 27(9):1336-1344. PubMed ID: 34020033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey.
    Murhekar MV; Bhatnagar T; Selvaraju S; Saravanakumar V; Thangaraj JWV; Shah N; Kumar MS; Rade K; Sabarinathan R; Asthana S; Balachandar R; Bangar SD; Bansal AK; Bhat J; Chopra V; Das D; Deb AK; Devi KR; Dwivedi GR; Khan SMS; Kumar CPG; Kumar MS; Laxmaiah A; Madhukar M; Mahapatra A; Mohanty SS; Rangaraju C; Turuk A; Baradwaj DK; Chahal AS; Debnath F; Haq I; Kalliath A; Kanungo S; Kshatri JS; Lakshmi GGJN; Mitra A; Nirmala AR; Prasad GV; Qurieshi MA; Sahay S; Sangwan RK; Sekar K; Shukla VK; Singh PK; Singh P; Singh R; Varma DS; Viramgami A; Panda S; Reddy DCS; Bhargava B;
    Lancet Glob Health; 2021 Mar; 9(3):e257-e266. PubMed ID: 33515512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers.
    Lumley SF; O'Donnell D; Stoesser NE; Matthews PC; Howarth A; Hatch SB; Marsden BD; Cox S; James T; Warren F; Peck LJ; Ritter TG; de Toledo Z; Warren L; Axten D; Cornall RJ; Jones EY; Stuart DI; Screaton G; Ebner D; Hoosdally S; Chand M; Crook DW; O'Donnell AM; Conlon CP; Pouwels KB; Walker AS; Peto TEA; Hopkins S; Walker TM; Jeffery K; Eyre DW;
    N Engl J Med; 2021 Feb; 384(6):533-540. PubMed ID: 33369366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
    Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
    Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of SARS-CoV-2 antibodies, associated factors, experiences and attitudes of nursing home and home healthcare employees in Switzerland.
    West EA; Kotoun OJ; Schori LJ; Kopp J; Kaufmann M; Rasi M; Fehr J; Puhan MA; Frei A;
    BMC Infect Dis; 2022 Mar; 22(1):259. PubMed ID: 35296242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
    Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
    Front Immunol; 2021; 12():626609. PubMed ID: 34084161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perceptions of immunity and vaccination certificates among the general population: a nested study within a serosurvey of anti-SARS-CoV-2 antibodies (SEROCoV-POP).
    Nehme M; Stringhini S; Guessous I; SEROCoV-Pop Study Team
    Swiss Med Wkly; 2020 Nov; 150():w20398. PubMed ID: 33202421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.